
Receptor BioLogix closes $33.6mm Series A round
Executive Summary
Receptor BioLogix (protein therapeutics for cancer and autoimmune and metabolic disorders) brought in $33.6mm with its Series A financing round led by Skyline Ventures. Other participants were Domain Associates, Essex Woodlands Health Ventures, MedImmune Ventures, Takeda Research Investment, and Northwest Technology Ventures.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com